Skip to main content

Doxorubicin (International)

In the US, Doxorubicin (doxorubicin systemic) is a member of the drug class antibiotics/antineoplastics and is used to treat Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Bladder Cancer, Breast Cancer, Bronchogenic Carcinoma, Cancer, Diffuse Large B-Cell Lymphoma, Hodgkin's Lymphoma, Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Neuroblastoma, Osteosarcoma, Ovarian Cancer, Soft Tissue Sarcoma, Stomach Cancer, Thyroid Cancer and Wilms' Tumor.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01DB01

CAS registry number (Chemical Abstracts Service)

0023214-92-8

Chemical Formula

C27-H29-N-O11

Molecular Weight

544

Therapeutic Category

Antineoplastic agent: Cytotoxic antibacterial from the group of anthracyclines

Chemical Name

5,12-Naphtacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-metoxy-, (8S-cis)-

Foreign Names

Generic Names

Brand Names

Glossary

TermDefinition
BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Search international drugs